Alogrefele in tumorile osoase benigne
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
850 10
Ultima descărcare din IBN:
2023-04-30 17:37
Căutarea după subiecte
similare conform CZU
616.718-006.03-089.843 (1)
Patologia organelor de locomoţie. Sistemul osos şi locomotor (462)
SM ISO690:2012
GROZA, Costina, DASCALIUC, Ion, TOPOR, Boris. Alogrefele in tumorile osoase benigne. In: Curierul Medical, 2016, nr. 3(59), pp. 114-119. ISSN 1875-0666.
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Curierul Medical
Numărul 3(59) / 2016 / ISSN 1875-0666

Alogrefele in tumorile osoase benigne
CZU: 616.718-006.03-089.843

Pag. 114-119

Groza Costina1, Dascaliuc Ion2, Topor Boris1
 
1 Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“,
2 IMSP Institutul Oncologic
 
Disponibil în IBN: 25 iulie 2016


Rezumat

Background: Bone morphogenetic proteins (BMPs) are essential mediators of bone formation involved in the regulation of differentiation of osteoprogenitor cells into osteoblasts. By their osteoinductive capacities, BMPs have been considered as the most potent growth factors that can promote the bone regeneration and repair, representing an important alternative to bone autotransplant. Material and methods: Underlying work is accumulated material within the Department of General Oncology and Rehabilitation Oncology Institute of Moldova. There were supervised 572 patients with benign tumors in the period from 2005 to 2015. Results: Tests revealed that the most frequent benign tumors are cartilaginous ones: osteocondroms 39 to 2.0 %, condroms 14 to 1.5%, condroblastoms – 2 to 0.6%. After cartilaginous tumors, second place is occupied by osteoclastoma. Rarely, patients with bone cyst and osteodisplastic fibrous bone lipoma are uncounted. Other processes are rarely encountered. Benign tumors more often prevail at men (58 ± 2%). Conclusions: Experimental and clinical studies suggested a great potential of BMPs in bone formation, especially in critical size bone defects. We may expect that the transplant for bone defects recovery that would satisfy the requirements of oncology can be developed.

Cuvinte-cheie
benign tumors,

allograft, bone regeneration